Objectives To assess the risk of serious upper gastrointestinal bleeding associated with the
newer antithrombotic agents used alone or in combination with other antithrombotic drugs; …

Objectives: We sought to describe the incidence of late angiographic stent thrombosis
(LAST) events in an unselected drug-eluting stent (DES) population. Background: Concerns …

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …

Recurrent strokes make up almost 25% of the nearly 800,000 strokes that occur annually in
the United States. Risk factors for ischemic stroke include hypertension, diabetes mellitus …

Prevention of early recurrent ischaemic stroke remains a priority in people with TIA or
ischaemic stroke. A number of trials have recently been completed assessing the efficacy of …

Background—Whether stroke patients should be investigated for asymptomatic coronary
artery disease remains matter of debate. Absolute risks of myocardial infarction (MI) and …

Upper gastrointestinal bleeding (UGIB) is defined as hemorrhage that involves the mouth to
the duodenum proximal to the ligament of Treitz. Common causes of UGIB include peptic …

Background & Aims Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists
(H2RAs) suppress gastric acid production, which can inhibit iron absorption. However, few …

This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …

Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …